The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 283-288

  Barreto, Jason N ^a   Beach, Cassidy L ^b   Wolf, Robert C ^a   Merten, Julianna A ^a   Tosh, Pritish K ^a   Wilson, John W ^a   Hogan, William J ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE; ARSENIC TRIOXIDE; CASPOFUNGIN; CLOFARABINE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MITOXANTRONE; RETINOIC ACID; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL PROPHYLAXIS; ARTICLE; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FLOW CYTOMETRY; FOLLOW UP; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; INDUCTION CHEMOTHERAPY; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; RASH; RHIZOPUS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMIC MYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLUS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RHIZOPUS; TRIAZOLES;

EID: 84875604950     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23388     Document Type: Article

References (31)

1. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-284.
2. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89-99.
3. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:692-701.
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-93.
5. Baden LR, Bensinger W, Casper C, et al. The NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM) Prevention and Treatment of Cancer-Related Infections (Version 2.2011). © 2009 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed May 11, 2012.
6. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
7. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.
8. Noxafil (posaconazole) oral suspension [package insert]. Summit, NJ: Schering-Plough, 2006.
9. Nagappan V, Deresinski S. Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-1617.
10. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-222.
11. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-966.
12. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-1883.
13. Cornely OA, Helfgott D, Langston A, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012;56:2652-2658.
14. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88:115-119.
15. Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 2011;89:351-352.
16. Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56:2806-2813.
17. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
18. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.
19. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
20. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-5118.
21. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
22. ® Aspergillus EIA [package insert]. Redmond, WA: Bio-Rad; 2003.
23. National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_ 4.03_2010-06-14_QuickReference_5x7.pdf. Accessed June 14, 2011.
24. Miyakis S, van Hal SJ, Ray J, et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010;16:927-933.
25. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:509-513.
26. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211.
27. Ruping MJ, Muller C, Vehreschild JJ, et al. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses 2011;54:230-233.
28. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin Infect Dis 2012;55:1080-1087.
29. Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: Real life multicentre experience. Mycoses 2012;55:483-492.
30. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012;55:381-390.
31. Trifilio SM, Yarnold PR, Scheetz MH, et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009;53:1793-1796.